

- strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. *Pediatr Nephrol.* 2021;36(5):1175-1182. doi: 10.1007/s00467-020-04811-0.
189. Majeranowski A, Okrój M. Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. *Pediatr Nephrol.* 2021;36(6):1651-1652. doi: 10.1007/s00467-021-04981-5.
190. Benoit SW, Khandelwal P, Grimley MS. A case of treatment-resistant membranous nephropathy associated with graft versus host disease successfully treated with daratumumab. *Pediatr Transplant.* 2022;26(4):e14263. doi: 10.1111/petr.14263.
191. Doberer K, Kläger J, Gualdoni GA, et al. CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft rejection. *Transplantation.* 2021;105(2):451-457. doi: 10.1097/TP.0000000000003247.
192. Ejaz K, Roback JD, Stowell SR, et al. Sullivan HC. Daratumumab: Beyond Multiple Myeloma. *Transfus Med Rev.* 2021;35(3):36-43. doi: 10.1016/j.tmr.2021.06.002.
193. Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. *Blood Cancer J.* 2021;11(12):192. doi: 10.1038/s41408-021-00587-0.
194. Gundesen MT, Lund T, Moeller HEH, et al. Plasma Cell Leukemia: Definition, Presentation, and Treatment. *Curr Oncol Rep.* 2019;21(1):8. doi: 10.1007/s11912-019-0754-x.
195. Gowin K, Skerget S, Keats JJ, et al. Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment. *Leuk Res.* 2021;111:106687. doi: 10.1016/j.leukres.2021.106687.
196. Žárská M, Vrabel D, Bezdekova R, et al. Plasma Cell Leukemia – the Forgotten Disease. *Klin Onkol.* 2019;32(1):40-46.
197. Parrondo RD, Moustafa MA, Reeder C, et al. Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. *Clin Lymphoma Myeloma Leuk.* 2021;21(5):355-360. doi: 10.1016/j.clml.2021.01.002.
198. Nalghranyan S, Singh AP, Schinke C. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. *Am J Hematol.* 2020;95(2):E34-E35. doi: 10.1002/ajh.25676.
199. Yang CL, Jiang NG, Zhang L, et al. Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation. *Ther Adv Hematol.* 2021;12:2040620721989578. doi: 10.1177/2040620721989578.
200. Ueno T, Sugio Y, Ohta T, et al. Successful upfront cord blood transplantation for plasma cell leukemia in the first complete response after daratumumab therapy. *Int J Hematol.* 2021;113(6):941-944. doi: 10.1007/s12185-021-03082-1.
201. Glavey SV, Flanagan L, Bleach R, et al. Secondary plasma cell leukaemia treated with single agent venetoclax. *Br J Haematol.* 2020;190(4):e242-e245. doi: 10.1111/bjh.16858.
202. Dittus C, Miller JA, Wehbie R, et al. Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma. *Br J Haematol.* 2022. doi: 10.1111/bjh.18228.
203. Roché P, Venton G, Berda-Haddad Y, et al. Could daratumumab induce the maturation of plasmablasts in Plasmablastic lymphoma? Potential therapeutic applications. *Eur J Haematol.* 2021;106(4):589-592. doi: 10.1111/ejh.13584. Epub 2021; PMID: 33469987.
204. Kathrotiya M, Radhakrishnan VS, Bhavé SJ, et al. Relapsed plasmablastic lymphoma in a HIV-negative patient: Pushing the envelope. *Clin Case Rep.* 2020;9(2):873-877. doi: 10.1002/ccr3.3673.
205. Ramadas P, Williams M, Duggan DB. Plasmablastic Lymphoma or Plasmablastic Myeloma: A Case of Post-Transplant Lymphoproliferative Disorder. *Case Rep Hematol.* 2021;4354941.
206. Iversen KF, Holdgaard PC, Preiss B, et al. Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report. *Haematologica.* 2019;104(9):e432-e433. doi: 10.3324/haematol.2018.214635.
207. Paulus A, Manna A, Akhtar S, et al. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. *Br J Haematol.* 2018;183(2):196-211. doi: 10.1111/bjh.15515.
208. Castillo JJ, Libby EN, Ansell SM, et al. Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. *Blood Adv.* 2020;4(20):5089-5092. doi: 10.1182/bloodadvances.2020003087.
209. Vidal-Crespo A, Matas-Céspedes A, Rodríguez V, et al. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. *Haematologica.* 2020;105(4):1032-1041. doi: 10.3324/haematol.2018.211904.
210. Mustafa N, Nee AHF, Chooi JY, et al. Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma. *J Immunother Cancer.* 2021;9(7):e002123. doi: 10.1136/jitc-2020-002123.
211. Vočková P, Svatoň M, Pokorná E, et al. Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma. *Folia biologica.* 2020;66(1):17-23.
212. Salles G, Gopal AK, Minnema MC, et al. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. *Clin Lymphoma Myeloma Leuk.* 2019;19(5):275-284. doi: 10.1016/j.clml.2018.12.013.
213. Panaampon J, Kariya R, Okada S. Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma. *Cancer Immunol Immunother.* 2022;71(5):1017-1031. doi: 10.1007/s00262-021-03054-8.
214. Shah NN, Singavi AK, Harrington A. Daratumumab in Primary Effusion Lymphoma. *N Engl J Med.* 2017;379(7):689-690. doi: 10.1056/NEJMc1806295.
215. Huang H, Zhu J, Yao M, et al. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. *J Hematol Oncol.* 2021;14(1):25-30. doi: 10.1186/s13045-020-01020-y.
216. Aeppli S, Driessen C, Graf L, Hitz F. Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab. *Hematol Oncol.* 2018;36(4):713-714. doi: 10.1002/hon.2533.
217. Písačka M, Králová M. Daratumumab – terapeutická monoklonální protilátka jako zdroj komplikací při imunohematologických vyšetřeních. *Transfuzie a hematologie dnes.* 2016;22(Suppl. 2): p. 29.
218. Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. *Transfusion.* 2015;55:1545-1554.
219. Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. *Transfusion.* 2015;55:1555-1562.
220. Sullivan HC, Gerner-Smidt C, Nooka AK, et al. Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. *Blood.* 2017;129:3033-3037.
221. Moreau P, van de Donk NW, San Miguel J, et al. Practical considerations for the use of daratumumab, a novel CD38 monoclonal antibody, in myeloma. *Drugs.* 2016;76:853-867.
222. McCudden C, Axel A, Slaets D, et al. Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody. *J Clin Oncol.* 2015;33:8590-8594.
223. Immunofixation, Daratumumab-Specific, Serum. 2020. Available from: <https://www.labcorp.com/tests/123218/immunofixation-daratumumab-specific-serum>.
224. Mills JR, Kohlhagen MC, Willich MAV, et al. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. *Blood* 2018;132:670-672.
225. Vakili H, Koorse Germans S, et al. Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study. *Diagnostics (Basel).* 2020;10(4):219. doi: 10.3390/diagnostics10040219.
226. Geirnaert M, Howarth J, Martin K, et al. A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting. *J Oncol Pharm Pract.* 2021;27(4):907-910. doi: 10.1177/1078155220967738.
227. Usmani SZ, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. *Blood.* 2019;134:668-677.
228. Nooka AK, Gleason C, Sargeant MO, et al. Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. *J Oncol Pract.* 2018;14(7):414-422. doi: 10.1200/JOP.18.00143.
229. Moore DC, Arnall JR, Thompson DL, et al. Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab. *Clin Lymphoma Myeloma Leuk.* 2020;20(10):e777-e781. doi: 10.1016/j.clml.2020.05.024.
230. Mateos MV, Nahi H, Legie W, et al. Subcutaneous versus intravenous daratumumab in relapsed or relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. *Lancet Haematol.* 2020;7(5):e370-e380. doi: 10.1016/S2352-3026(20)30070-3.
231. Chari A, Rodríguez-Otero P, Maisnar V. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. *British journal of haematology.* 2021;192(5):869-878.
232. Johnsrud AJ, Johnsrud JJ, Susanibar SA, et al. Infectious and immunological sequelae of daratumumab in multiple myeloma. *Br. J. Haematol.* 2019;185(1):187-189. <https://doi.org/10.1111/bjh.15433>.
233. Burns EA, Ensor JE, Anand K, et al. Opportunistic Infections in Patients Receiving Daratumumab Regimens for Multiple Myeloma (MM) Blood. 2021;138(Supplement 1):4740. <https://doi.org/10.1182/blood-2021-152068>.
234. Nahi H, Chrobok M, Gran C, et al. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. *PLoS One.* 2019;14(2):e0211927. doi: 10.1371/journal.pone.0211927.
235. Lee SK, Sung PS, Park SS, et al. Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma. *Clin Infect Dis.* 2021;73(6):e1372-e1375. doi: 10.1093/cid/ciab302.
236. Frerichs KA, Bosman PWC, Nijhof IS, et al. Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment. *Clin Lymphoma Myeloma Leuk.* 2019;19(1):e9-e11. doi: 10.1016/j.clml.2018.10.002.
237. Verpoorte-Botden IGP, Minnema MC, et al. EBV-related lymphoma after long-term daratumumab treatment: a case report. *Blood Cancer J.* 2020;10(11):113. doi: 10.1038/s41408-020-00379-y.
238. Reddy K, Htut M, Krishnan A, et al. Aseptic Meningitis as a Complication of Daratumumab Therapy. *Clin Lymphoma Myeloma Leuk.* 2018;18(8):e333-e335. doi: 10.1016/j.clml.2018.05.018.
239. Nakamura F, Nasu R. Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia. *Ann Hematol.* 2019;98(9):2231-2232. doi: 10.1007/s00277-019-03711-0.
240. Girmenia C, Cavo M, Corso A, et al. Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel. *Crit Rev Oncol Hematol.* 2022;172:103623. doi: 10.1016/j.critrevonc.2022.103623.
241. Braga BP, Prieto-González S, et al. Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases. *Med Clin (Barc).* 2019;152(12):502-507. doi: 10.1016/j.medcli.2019.01.010.
242. Cooley L, Dendle C, Wolf J, et al. Consensus guidelines